• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Terphenyls M-terphenyls
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives M-terphenyls

Introduction to 2,4,6-Tris(m-terphenyl-5'-yl)boroxin (CAS No. 909407-14-3) in Modern Chemical Research

2,4,6-Tris(m-terphenyl-5'-yl)boroxin, identified by the Chemical Abstracts Service Number (CAS No.) 909407-14-3, represents a sophisticated boron-containing heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical innovation. This compound belongs to the class of boroxines, which are known for their unique structural and electronic properties, making them valuable scaffolds in the design of novel therapeutic agents. The presence of multiple terphenyl substituents in its molecular structure endows it with enhanced steric and electronic tunability, which is a critical factor in its potential application as a pharmacophore.

The molecular architecture of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin consists of a central boroxine ring linked to three bulky m-terphenyl groups. This particular arrangement imparts exceptional rigidity and lipophilicity to the molecule, characteristics that are highly desirable in drug development for improving membrane permeability and target binding affinity. Boroxines have been extensively studied for their ability to interact with biological targets through coordination with metal ions and other biomolecules, a property that has been exploited in various therapeutic contexts.

In recent years, the exploration of boron-containing compounds in medicinal chemistry has expanded dramatically, driven by their diverse biological activities and synthetic versatility. The introduction of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin into this landscape represents a significant advancement, particularly in the context of developing next-generation anticancer agents. Boron complexes have long been recognized for their efficacy in targeted therapies, such as boron neutron capture therapy (BNCT), where they selectively accumulate in tumor tissues and undergo radioactive decay upon irradiation.

One of the most compelling aspects of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin is its potential as a modulator of enzyme activity. Preliminary studies have suggested that this compound may interact with specific proteases and kinases involved in cancer progression. The bulky terphenyl groups not only enhance binding affinity but also provide a platform for further derivatization, allowing chemists to fine-tune its pharmacological profile. This flexibility is particularly important in addressing the challenges posed by drug resistance, where compounds with adjustable properties can be tailored to overcome resistant mechanisms.

The synthesis of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin presents unique challenges due to its complex structure. However, advances in synthetic methodologies have made it increasingly feasible to produce this compound on a scalable basis. Modern techniques such as transition-metal-catalyzed cross-coupling reactions have enabled the efficient construction of the terphenyl moieties, while protecting group strategies have been employed to ensure regioselective functionalization of the boroxine ring.

The boron atom in 2,4,6-Tris(m-terphenyl-5'-yl)boroxin serves as a critical pharmacophoric center, facilitating interactions with various biological targets. Boron-containing heterocycles have been shown to exhibit broad-spectrum activity against pathogens and malignancies by interfering with essential metabolic pathways or by directly inhibiting key enzymes. The ability of boroxines to chelate metal ions has also been leveraged in designing compounds that can disrupt metal-dependent processes in pathogens.

Recent research has highlighted the potential of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin as an antiviral agent. Viruses rely on host cellular machinery for replication and survival, making them vulnerable to compounds that disrupt these processes. Studies indicate that this boron derivative may inhibit viral proteases or integrases by competing with natural substrates or by inducing conformational changes that impair viral function. The lipophilic nature of the terphenyl groups enhances its ability to penetrate viral envelopes, further improving its antiviral efficacy.

The development of 2,4,6-Tris(m-terphenyl-5'-yl)boroxin also aligns with emerging trends in green chemistry and sustainable drug design. Boron chemistry offers several advantages over traditional heavy metal-based therapeutics due to its lower toxicity profile and higher biodegradability. By incorporating renewable resources into its synthesis and minimizing waste generation during production processes, researchers are paving the way for environmentally friendly pharmaceuticals.

In conclusion,2,4,6-Tris(m-terphenyl-5'-yl)boroxin (CAS No. 909407-14-3) stands out as a promising candidate for further exploration in medicinal chemistry and chemical biology. Its unique structural features and versatile biological activities make it an attractive scaffold for developing novel therapeutic agents with applications ranging from oncology to antiviral treatments. As research continues to uncover new insights into its mechanism of action and potential applications,2,4,6-Tris(m-terphenyl-5'-yl)boroxin is poised to play a significant role in shaping the future of drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)